Ultragenyx Pharmaceutical (RARE) stock: insider trades, news & valuation
Heavy sellingShare price and insider trades
Ultragenyx Pharmaceutical insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $4.0M of RARE stock on the open market.
Get emailed when insiders cluster-buy stocks like RARE
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
RARE insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $340K | 5 |
| Q2 2026 | — | 0 | $575K | 7 |
| Q1 2026 | — | 0 | $2.7M | 13 |
| Q4 2025 | — | 0 | $365K | 3 |
Valuation, profit and volume
Summary
Over the past 12 months, 0 Ultragenyx Pharmaceutical Inc. insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $4.0M. 15 of 28 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 15SEC | Theodore Alan HuizengaSvp, Chief Accounting Officer | Sell Plan | 1,28367,863 held (−2%) | $13.57 | $17K | +14.1% | — |
| Sep 8SEC | Theodore Alan HuizengaSvp, Chief Accounting Officer | Sell | 16169,146 held (−0%) | $13.99 | $2K | +10.7% | — |
| Aug 4SEC | Howard HornCFO | Sell Plan | 4,69696,295 held (−5%) | $24.92 | $117K | -37.9% | — |
| Aug 4SEC | Karah Herdman ParschauerGeneral Counsel | Sell Plan | 1,90092,562 held (−2%) | $24.92 | $47K | -37.9% | — |
| Jul 6SEC | Howard HornCFO | Sell Plan | 4,698100,991 held (−4%) | $33.13 | $156K | -53.3% | — |
| Jun 15SEC | Corazon (corsee) D. SandersDirector | Sell | 2,00021,095 held (−9%) | $25.05 | $50K | -38.2% | — |
| Jun 15SEC | Karah Herdman ParschauerGeneral Counsel | Sell Plan | 1,89994,462 held (−2%) | $24.62 | $47K | -37.1% | — |
| Jun 1SEC | Howard HornCFO | Sell Plan | 4,653105,689 held (−4%) | $23.77 | $111K | -34.9% | — |
| May 18SEC | Shehnaaz SulimanDirector | Sell Plan | 5,74027,951 held (−17%) | $25.12 | $144K | -38.4% | — |
| May 6SEC | Eric CrombezEvp And Chief Medical Officer | Sell | 344111,189 held (−0%) | $24.96 | $9K | -38.0% | — |
| May 4SEC | Howard HornCFO | Sell Plan | 4,683110,342 held (−4%) | $24.90 | $117K | -37.8% | — |
| Apr 2SEC | Howard HornCFO | Sell Plan | 4,68380,351 held (−6%) | $20.97 | $98K | -26.2% | — |
| Mar 10SEC | Karah Herdman ParschauerGeneral Counsel | Sell | 6,01870,328 held (−8%) | $21.40 | $129K | -27.7% | — |
| Mar 10SEC | Karah Herdman ParschauerGeneral Counsel | Sell | 3,50866,820 held (−5%) | $22.67 | $80K | -31.7% | — |
| Mar 3SEC | Emil D KakkisCEO, President | Sell | 54,404658,994 held (−8%) | $22.80 | $1.2M | -32.1% | — |
| Mar 3SEC | Erik HarrisEvp & Chief Commercial Officer | Sell | 10,53989,515 held (−11%) | $22.80 | $240K | -32.1% | — |
| Mar 3SEC | John Richard PinionSee Remarks | Sell | 10,029110,026 held (−8%) | $22.80 | $229K | -32.1% | — |
| Mar 3SEC | Karah Herdman ParschauerGeneral Counsel | Sell | 8,13576,346 held (−10%) | $22.80 | $185K | -32.1% | — |
| Mar 3SEC | Eric CrombezEvp And Chief Medical Officer | Sell | 7,02976,301 held (−8%) | $22.80 | $160K | -32.1% | — |
| Mar 3SEC | Howard HornCFO | Sell Plan | 5,29089,788 held (−6%) | $22.80 | $121K | -32.1% | — |
| Mar 3SEC | Howard HornCFO | Sell Plan | 3,11986,669 held (−3%) | $22.54 | $70K | -31.3% | — |
| Mar 3SEC | Theodore Alan HuizengaSvp, Chief Accounting Officer | Sell | 1,63248,670 held (−3%) | $22.80 | $37K | -32.1% | — |
| Mar 3SEC | Howard HornCFO | Sell Plan | 1,63585,034 held (−2%) | $22.40 | $37K | -30.9% | — |
| Feb 3SEC | Howard HornCFO | Sell Plan | 3,06188,935 held (−3%) | $23.56 | $72K | -34.3% | — |
| Jan 5SEC | Howard HornCFO | Sell Plan | 3,15091,996 held (−3%) | $22.84 | $72K | -32.2% | — |
| Dec 30SEC | Theodore Alan HuizengaSvp, Chief Accounting Officer | Sell | 8550,450 held (−0%) | $34.38 | $3K | -55.0% | — |
| Dec 11SEC | Howard HornCFO | Sell Plan | 3,08195,146 held (−3%) | $36.38 | $112K | -57.4% | — |
| Oct 14SEC | Howard HornCFO | Sell | 7,94298,227 held (−7%) | $31.51 | $250K | -50.9% | — |
Insiders at Ultragenyx Pharmaceutical Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Howard HornCFO | — | $1.3M | Aug 4, 2026 | — |
| Emil D KakkisCEO, President | — | $1.2M | Mar 3, 2026 | — |
| Karah Herdman ParschauerGeneral Counsel | — | $488K | Aug 4, 2026 | — |
| Erik HarrisEvp & Chief Commercial Officer | — | $240K | Mar 3, 2026 | — |
| John Richard PinionSee Remarks | — | $229K | Mar 3, 2026 | — |
| Eric CrombezEvp And Chief Medical Officer | — | $169K | May 6, 2026 | — |
| Shehnaaz SulimanDirector | — | $144K | May 18, 2026 | — |
| Theodore Alan HuizengaSvp, Chief Accounting Officer | — | $60K | Sep 15, 2026 | — |
| Corazon (corsee) D. SandersDirector | — | $50K | Jun 15, 2026 | — |
RARE stock: common questions
Are Ultragenyx Pharmaceutical Inc. insiders buying RARE stock?
In the past 12 months, 0 insiders reported open-market purchases of RARE worth $0.
Are Ultragenyx Pharmaceutical Inc. insiders selling RARE stock?
9 insiders reported sales worth $4.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is RARE's 52-week range?
Over the past year RARE has traded between $12.88 and $36.54. It last closed at $15.48 on Oct 9, 2026.